Ketamine Treatments of Neuropsychiatric Disorders: What We Have Learned From Over a Quarter Century of Experience

Gerard Sanacora, MD, PhD • George D. Gross and Esther S. Gross Professor of Psychiatry • Director, Yale Depression Research Program • Co-Director, Yale New Haven Hospital Interventional Psychiatry Service • Yale University School of Medicine

Learning objectives:
Upon completion of this activity, participants will be able to:

• Discuss the rationale underlying and history of the development of ketamine as an antidepressant agent
• Better critically evaluate the longer-term data associated with thte use of esketamine nasal spray for major depressive disorder
• More fully understand the complex contextual issues that complicate the study and clinical implementation of ketamine and other rapidly acting antidepressant agents.

----------

In addition to the Pritzker Building, DPBS members can also watch this event live at Mount Zion (Room B730) and ZSFG (Bldg. 5, Room 7E12), as well as on Zoom (psychiatry.ucsf.edu/watchgrandrounds).

Psychiatry and Behavioral Sciences Grand Rounds presentations are for educational purposes and intended only for behavioral/mental health professionals and clinical providers.

Continuing education (CE) credit is available for physicians, psychologists, nurses, and therapists who participate in this activity.